Filtros de búsqueda

Lista de obras de Carlo Gambacorti-Passerini

A Bioinformatics Procedure to Identify and Annotate Somatic Mutations in Whole-Exome Sequencing Data

A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation

artículo científico publicado en 2020

A mechanistic design principle for protein tyrosine kinase sensors: application to a validated cancer target.

artículo científico publicado en 2007

A needle in a haystack: Identifying biomarkers to personalize systemic therapy in patients with hepatocellular carcinoma

artículo científico publicado en 2013

A rapid method for the purification of wild-type and V804M mutant ret catalytic domain: A tool to study thyroid cancer

artículo científico publicado en 2006

ALK a novel lymphoma-associated tumor antigen for vaccination strategies

artículo científico publicado en 2003

ALK as a novel lymphoma-associated tumor antigen: identification of 2 HLA-A2.1-restricted CD8+ T-cell epitopes

artículo científico publicado en 2002

ALK inhibitors for clinical use in cancer therapy

artículo científico

Abl inhibitor BMS354825 binding mode in Abelson kinase revealed by molecular docking studies

artículo científico publicado en 2005

Abrupt Relapse of ALK-Positive Lymphoma after Discontinuation of Crizotinib.

artículo científico publicado en 2016

Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants

artículo científico publicado en 2008

Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK.

artículo científico publicado en 2015

Acute promyelocytic leukaemia cells resistant to retinoic acid show further perturbation of the RAR alpha signal transduction system.

artículo científico publicado en 1995

Additive antisense effects of different PNAs on the in vitro translation of the PML/RARalpha gene

artículo científico publicado en 1998

Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients

artículo científico publicado en 2015

Adoptive immunotherapy of advanced melanoma patients with interleukin-2 (IL-2) and tumor-infiltrating lymphocytes selected in vitro with low doses of IL-2

artículo científico publicado en 1993

Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Workshop

artículo científico

Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study

artículo científico publicado en 2015

Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients

artículo científico publicado en 2003

Alterations in creatine kinase, phosphate and lipid values in patients with chronic myeloid leukemia during treatment with imatinib

artículo científico publicado en 2008

An enzyme-linked immunosorbent assay to screen for inhibitors of the oncogenic anaplastic lymphoma kinase.

artículo científico publicado en 2005

Anaplastic lymphoma kinase and its signalling molecules as novel targets in lymphoma therapy.

artículo científico publicado en 2005

BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and in chronic phase/blast crisis CML patients

artículo científico publicado en 2010

BCR-ABL nuclear entrapment kills human CML cells: ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B.

artículo científico publicado en 2005

BCR-ABL oncoprotein is expressed by platelets from CML patients and associated with a special pattern of CrkL phosphorylation

artículo científico publicado en 1998

BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2.

artículo científico publicado en 2001

BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene

artículo científico publicado en 2015

BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells

artículo científico publicado en 2008

Bcl-XL down-regulation suppresses the tumorigenic potential of NPM/ALK in vitro and in vivo

artículo científico publicado en 2003

Bcr-Abl mutations, resistance to imatinib, and imatinib plasma levels

artículo científico publicado en 2003

Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation

artículo científico publicado en 2007

Binding of imatinib by alpha(1)-acid glycoprotein

artículo científico publicado en 2002

Bosutinib : a review of preclinical and clinical studies in chronic myelogenous leukemia

artículo científico

Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial.

artículo científico publicado en 2017

Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up

artículo científico publicado en 2014

Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure

scientific article published on 27 February 2012

Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors

artículo científico publicado en 2013

Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial

artículo científico publicado en 2014

Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial

artículo científico publicado en 2012

Bosutinib: a review of preclinical studies in chronic myelogenous leukaemia

artículo científico publicado en 2010

CANCER PROCOAGULANT AND HAEMOSTATIC ANBORMALITIES IN MELANOMA

scientific article published in The Lancet

CEQer: a graphical tool for copy number and allelic imbalance detection from whole-exome sequencing data

artículo científico publicado en 2013

Characterization of compound 584, an Abl kinase inhibitor with lasting effects

artículo científico publicado en 2008

Characterization of some molecular mechanisms governing autoactivation of the catalytic domain of the anaplastic lymphoma kinase.

artículo científico publicado en 2007

Choosing the right TKI for chronic myeloid leukemia: when the truth lies in "long-term" safety and efficacy

artículo científico publicado en 2011

Chronic myeloid leukemia 2011: successes, challenges, and strategies--proceedings of the 5th annual BCR-ABL1 positive and BCR-ABL1 negative myeloproliferative neoplasms workshop

artículo científico publicado en 2011

Chronic myeloid leukemia: Second-line drugs of choice.

artículo científico publicado en 2015

Chronic myeloid leukemia: reminiscences and dreams

artículo científico publicado en 2016

Clinical and biological implications of driver mutations in myelodysplastic syndromes

artículo científico publicado en 2013

Colorectal Tumors Are Effectively Eradicated by Combined Inhibition of -Catenin, KRAS, and the Oncogenic Transcription Factor ITF2

artículo científico publicado en 2010

Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells.

artículo científico publicado en 2018

Constitutive activation of Jak2 contributes to proliferation and resistance to apoptosis in NPM/ALK-transformed cells

artículo científico publicado en 2003

Crizotinib in Anaplastic Large-Cell Lymphoma ⬇️

artículo científico publicado el 24 de febrero de 2011

Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients

artículo científico publicado en 2014

Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors

artículo científico publicado en 2012

Current management of CML patients: Summary of the Italian Consensus Meeting held in Rome, April 11-12, 2013.

artículo científico

Decrease of resistance to imatinib in leukaemia

artículo científico publicado en 2002

Deferasirox in the management of iron-overload in patients with myelofibrosis: a multicentre study from the Rete Ematologica Lombarda (IRON-M study)

artículo científico publicado en 2019

Design, synthesis, and biological activity of urea derivatives as anaplastic lymphoma kinase inhibitors.

artículo científico publicado en 2011

Determination of alpha-1 acid glycoprotein in patients with Ph+ chronic myeloid leukemia during the first 13 weeks of therapy with STI571.

artículo científico publicado en 2002

Development of c-Kit-expressing small-cell lung cancer in a chronic myeloid leukemia patient during imatinib treatment

artículo científico publicado en 2004

Differences between in vivo and in vitro sensitivity to imatinib of Bcr/Abl+ cells obtained from leukemic patients.

artículo científico publicado en 2002

Dissection of the RET/β-catenin interaction in the TPC1 thyroid cancer cell line.

artículo científico publicado en 2011

ERG deregulation induces PIM1 over-expression and aneuploidy in prostate epithelial cells

artículo científico publicado en 2011

ETNK1 mutations induce a mutator phenotype that can be reverted with phosphoethanolamine

artículo científico publicado en 2020

Effect of imatinib on haematopoietic recovery following idarubicin exposure.

artículo científico publicado en 2003

Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive Leukemias

artículo científico

Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.

artículo científico publicado en 2008

Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition.

artículo científico publicado en 2010

Epigenetic silencing of the proapoptotic gene BIM in anaplastic large cell lymphoma through an MeCP2/SIN3a deacetylating complex.

artículo científico publicado en 2013

ErbB-2 receptor cooperates with E6/E7 oncoproteins of HPV type 16 in breast tumorigenesis

artículo científico publicado en 2007

Erratum: Corrigendum: In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'

scholarly article published in Nature Medicine

Erratum: OncoScore: a novel, Internet-based tool to assess the oncogenic potential of genes

artículo científico publicado en 2017

Evidence for D276G and L364I Bcr-Abl mutations in Ph+ leukaemic cells obtained from patients resistant to Imatinib

artículo científico publicado en 2005

Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency

artículo científico publicado en 2015

Expression, purification, and inhibition of human RET tyrosine kinase

artículo científico publicado en 2005

FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia

artículo científico publicado en 2007

Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib

artículo científico publicado en 2015

Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment

artículo científico publicado en 2007

First-line treatment of 102 chronic myeloid leukemia patients with imatinib: a long-term single institution analysis.

artículo científico publicado en 2014

Focal adhesion kinase (FAK) binds RET kinase via its FERM domain, priming a direct and reciprocal RET-FAK transactivation mechanism.

artículo científico publicado en 2011

FusionAnalyser: a new graphical, event-driven tool for fusion rearrangements discovery

artículo científico publicado en 2012

Gene expression analysis fails to identify patients with chronic myeloid leukemia who will achieve cytogenetic response to imatinib.

artículo científico publicado en 2005

Gene expression signature of non-involved lung tissue associated with survival in lung adenocarcinoma patients.

artículo científico publicado en 2013

Gynaecomastia in men with chronic myeloid leukaemia after imatinib

artículo científico publicado en 2003

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

artículo científico publicado en 2002

How "precise" is precision medicine in hematology?

artículo científico publicado en 2017

How I treat newly diagnosed chronic myeloid leukemia in 2015.

artículo científico publicado en 2014

Identification of genetic polymorphisms modulating nausea and vomiting in two series of opioid-treated cancer patients

scientific article published on 17 January 2020

Identification of novel point mutations in splicing sites integrating whole-exome and RNA-seq data in myeloproliferative diseases

artículo científico publicado en 2013

Identification of novel point mutations in splicing sites integrating whole-exome and RNA-seq data in myeloproliferative diseases.

artículo científico publicado en 2014

Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis

artículo científico publicado en 2007

Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: A systematic review and a meta-analysis

artículo científico publicado en 2017

Imatinib does not substantially modify the glycemic profile in patients with chronic myeloid leukaemia

artículo científico publicado en 2009

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

artículo científico publicado en 2002

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

artículo científico publicado en 2002

Imatinib--A New Tyrosine Kinase Inhibitor for First-Line Treatment of Chronic Myeloid Leukemia in 2015.

artículo científico publicado en 2015

Imatinib-loaded polyelectrolyte microcapsules for sustained targeting of BCR-ABL+ leukemia stem cells.

artículo científico publicado en 2010

Immunogenicity of fusion proteins. An example of tumor-specific/transformation-related antigens.

artículo científico publicado en 1993

In Vitro Transcriptional and Translational Block of the bcl-2 Gene Operated by Peptide Nucleic Acid

article

In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells

artículo científico publicado en 2006

In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib

artículo científico publicado en 2015

In vivo T-cell immune response against anaplastic lymphoma kinase in patients with anaplastic large cell lymphomas

artículo científico publicado en 2006

Increased sFLT1/PlGF ratio in COVID-19: a novel link to Angiotensin II-mediated endothelial dysfunction

artículo científico publicado en 2020

Inhibition of RET tyrosine kinase by SU5416.

artículo científico publicado en 2006

Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis.

artículo científico publicado en 1997

Inhibitors of the RET tyrosine kinase based on a 2-(alkylsulfanyl)-4-(3-thienyl)nicotinonitrile scaffold

artículo científico publicado en 2010

Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patients

artículo científico publicado en 2015

Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia

scientific article published on 17 June 2019

Locking Src/Abl Tyrosine Kinase Activities Regulate Cell Differentiation and Invasion of Human Cervical Cancer Cells Expressing E6/E7 Oncoproteins of High-Risk HPV

artículo científico publicado en 2010

Long-term and low-dose of busulfan is a safe and effective second-line treatment in elderly patients with essential thrombocythemia resistant or intolerant to hydroxyurea.

artículo científico publicado en 2018

Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib

artículo científico publicado en 2016

Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors

artículo científico publicado en 2015

Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib

artículo científico publicado en 2016

Long-term patient-reported outcomes from an open-label safety and efficacy study of bosutinib in Philadelphia chromosome-positive chronic myeloid leukemia patients resistant or intolerant to prior therapy

artículo científico publicado en 2017

Lysis by interleukin 2-stimulated tumor-infiltrating lymphocytes of autologous and allogeneic tumor target cells

scientific article published on 01 January 1989

Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review

scholarly article by Jorge Eduardo Cortes et al published 27 December 2018 in Journal of Hematology & Oncology

Mitochondrial Hyperactivation and Enhanced ROS Production are Involved in Toxicity Induced by Oncogenic Kinases Over-Signaling

article

Molecular cytogenetics of the acute promyelocytic leukemia-derived cell line NB4 and of four all-trans retinoic acid-resistant subclones

artículo científico publicado en 2002

Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias.

artículo científico publicado en 2003

Morgana acts as an oncosuppressor in chronic myeloid leukemia.

artículo científico publicado en 2015

Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib

artículo científico publicado en 2011

Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients

artículo científico publicado en 2009

NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma

artículo científico publicado en 2007

NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922

artículo científico publicado en 2015

Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice

scientific article published on 28 February 2019

Of nicks and time

artículo científico publicado en 2001

Oncogenic fusion tyrosine kinases as molecular targets for anti-cancer therapy

artículo científico publicado en 2007

PNAs as novel cancer therapeutics

scholarly article by Luca Mologni & Carlo Gambacorti-Passerini published May 2003 in International Journal of Peptide Research and Therapeutics

Panniculitis during Dasatinib Therapy for Imatinib-Resistant Chronic Myelogenous Leukemia

article published in 2006

Part I: Milestones in personalised medicine--imatinib

artículo científico publicado en 2008

Peripheral blood progenitor cell collection in chronic myeloid leukemia patients with complete cytogenetic response after treatment with imatinib mesylate

artículo científico publicado en 2005

Personal history and quality of life in chronic myeloid leukemia patients: a cross-sectional study using narrative medicine and quantitative analysis

artículo científico publicado en 2016

Phenotypic and functional analysis of lymphocytes infiltrating paediatric tumours, with a characterization of the tumour phenotype

article

Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.

artículo científico publicado en 2018

Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase

artículo científico publicado en 2013

Procoagulant and fibrinolytic activity of human ovarian carcinoma cells in culture.

artículo científico publicado en 1986

Prognostic variables in patients with chronic myeloid leukemia treated with imatinib

artículo científico publicado en 2006

RET kinase inhibitors: a review of recent patents (2012-2015).

artículo científico publicado en 2016

RNA-seq is a valuable complement of conventional diagnostic tools in newly diagnosed AML patients

scholarly article by Rocco Piazza et al published 17 November 2015 in American Journal of Hematology

Recurrent ETNK1 mutations in atypical chronic myeloid leukemia.

artículo científico publicado en 2014

Recurrent SETBP1 mutations in atypical chronic myeloid leukemia

artículo científico publicado en 2013

Reply to P. Laneuville et al

Reversal of microRNA-150 silencing disadvantages crizotinib-resistant NPM-ALK(+) cell growth

artículo científico publicado en 2015

SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations

artículo científico publicado en 2013

SKI-606 decreases growth and motility of colorectal cancer cells by preventing pp60(c-Src)-dependent tyrosine phosphorylation of beta-catenin and its nuclear signaling

artículo científico publicado en 2006

STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma

artículo científico publicado en 2020

Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib

artículo científico publicado en 2011

Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase 1/2 study.

artículo científico publicado en 2018

Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia

artículo científico publicado en 2014

Selective cytotoxicity of betulinic acid on tumor cell lines, but not on normal cells

artículo científico publicado en 2002

Sensitivity to imatinib but low frequency of the TEL/PDGFRbeta fusion protein in chronic myelomonocytic leukemia

artículo científico publicado en 2003

Sensitivity to the abl inhibitor STI571 in fresh leukaemic cells obtained from chronic myelogenous leukaemia patients in different stages of disease

artículo científico publicado en 2001

Simultaneous development of Philadelphia chromosome-positive and -negative leukemias in the same patient

article

Somatic mutations identified at diagnosis by exome sequencing can predict response to imatinib in chronic phase chronic myeloid leukemia (CML) patients

artículo científico publicado en 2017

Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting

artículo científico publicado en 2009

Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting.

artículo científico publicado en 2007

Sphingosine kinase 1 overexpression is regulated by signaling through PI3K, AKT2, and mTOR in imatinib-resistant chronic myeloid leukemia cells.

artículo científico publicado en 2011

Structural Insights into the ATP Binding Pocket of the Anaplastic Lymphoma Kinase by Site-Directed Mutagenesis, Inhibitor Binding Analysis, and Homology Modeling

article

Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma

scientific article published on 20 September 2016

Synergistic activity of the Src/Abl inhibitor bosutinib in combination with imatinib

artículo científico publicado en 2010

Synergistic effects of combined Wnt/KRAS inhibition in colorectal cancer cells

artículo científico publicado en 2012

Synthesis and biological evaluation of benzo[4,5]imidazo[1,2-c]pyrimidine and benzo[4,5]imidazo[1,2-a]pyrazine derivatives as anaplastic lymphoma kinase inhibitors

artículo científico publicado en 2014

Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors

artículo científico publicado en 2010

Systemic administration of autologous, alloactivated helper-enriched lymphocytes to patients with metastatic melanoma of the lung. A phase I study.

artículo científico publicado en 1986

The ALK gene, an attractive target for inhibitor development

artículo científico publicado en 2011

The Novel PIM1 Inhibitor NMS-P645 Reverses PIM1-Dependent Effects on TMPRSS2/ERG Positive Prostate Cancer Cells And Shows Anti-Proliferative Activity in Combination with PI3K Inhibition

artículo científico publicado en 2017

The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with Imatinib mesylate predicts for prolonged response at 6 years.

artículo científico publicado en 2006

The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells

artículo científico publicado en 2007

Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.

artículo científico publicado en 2012

Too many agencies spoil Euro research

artículo científico publicado en 1999

Treatment Patterns in Patients with Chronic-Phase Chronic Myeloid Leukaemia in Routine Clinical Practice: the SIMPLICITY Italian Population.

artículo científico publicado en 2019

Unique substrate specificity of anaplastic lymphoma kinase (ALK): development of phosphoacceptor peptides for the assay of ALK activity

artículo científico publicado en 2005

Validation of PDGFRbeta and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib

artículo científico publicado en 2008

Valproic acid enhances bosutinib cytotoxicity in colon cancer cells

artículo científico publicado en 2009

c-MYC Generates Repair Errors via Increased Transcription of Alternative-NHEJ Factors, LIG3 and PARP1, in Tyrosine Kinase-Activated Leukemias

artículo científico publicado en 2015

hnRNP A1 nucleocytoplasmic shuttling activity is required for normal myelopoiesis and BCR/ABL leukemogenesis

artículo científico publicado en 2002

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda